Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Risk factors for hospitalization among older, incident haemodialysis patients
Schoonover, Kimberly , Hickson, LaTonya J. , Norby, Suzanne M. , Hogan, Marie C. , Chaudhary, Sanjay , Albright, Robert C. , McCarthy, James T. , Williams, Amy W. , Schoonover, Kimberly L, Dillon, John , Hickson, LaTonya J , Hogan, Marie C , Chaudhary, Sanjay

Nephrology | July 12, 2013 | Volume: 18 | Issue: 11 | Pages: 712-717

10.1111/nep.12129 | PMID 23848358 Get It

AbstractAimsThe number of elderly persons with end‐stage renal disease is increasing with many requiring hospitalizations. This study examines the causes and predictors of hospitalization in older haemodialysis patients.MethodsWe reviewed hospitalizations of older (≥65 years) incident chronic haemodialysis patients initiating therapy between 1 January 2007 and 31 December 2009 under the care of a single Midwestern United States dialysis provider.ResultsOf 125 patients, the mean age was 76 ± 7 years and 72% were male. At first dialysis, 68% used a central venous catheter (CVC) and 51% were in the hospital. Mean follow‐up was 1.8 ± 1.0 years. At least one hospitalization occurred in 89 (71%) patients and half of all patients were hospitalized once within the first 223 days. Total hospital admission rate was 1.48 per patient year with hospital days totalling 8.54 days per patient year. The three most common reasons for first admission were cardiac (33%), infection (18%) and gastrointestinal (12%). Predictors of future hospitalization included the first dialysis occurring in hospital (hazard ratios (HR) 2.1, 95% CI 1.4–3.3, P = 0.0005) and the use of a CVC at first haemodialysis (HR 2.6, CI 1.6–4.4, P < 0.0001).ConclusionHospitalizations are common in older incident haemodialysis patients. Access preparation and overall burden of illness leading to the initial hospitalization appear to play a role. Identification of additional factors associated with hospitalization will allow for focused interventions to reduce hospitalization rates and increase the value of care.
Depression Remission Decreases Outpatient Utilization at 6 and 12 Months after Enrollment into Collaborative Care Management
Angstman, Kurt B. , Oberhelman, Sara S. , Rohrer, James E. , Meunier, Matthew R. , Rasmussen, Norman H., Chappell, Daniel H.

Population Health Management | July 12, 2013 | Volume: 17 | Issue: 1 | Pages: 48-53

10.1089/pop.2013.0004 | PMID 23848475 Get It

Collaborative care management (CCM) for depression has been demonstrated to improve clinical outcomes. The impetus for this study was to determine if outpatient utilization patterns would be associated with depression outcomes. The hypothesis was that depression remission would be independently correlated with outpatient utilization at 6 and 12 months after enrollment into CCM. The study was a retrospective chart review analysis of 773 patients enrolled into CCM with 6- and 12-month follow-up data. The data set comprised baseline demographic data, patient intake self-assessment scores (Patient Health Questionnaire [PHQ-9], Generalized Anxiety Disorder-7, Mood Disorder Questionnaire, and Alcohol Use Disorders Identification Test), the number of outpatient visits, and follow-up PHQ-9 scores. To control for individual patient complexity and pattern of usage, the number of outpatient visits for 6 months prior to enrollment also was measured. With a logistic regression model for outpatient visit outlier status as the dependent variable, remission at 6 months (odds ratio [OR] 0.519, CI [confidence interval] 0.349–0.770, P =0.001) and remission at 12 months (OR 0.573, CI 0.354–0.927, P =0.023) were predictive. With this inverse relationship between remission and outlier status, those patients who were not in remission had an OR of 1.928 for outpatient visit outlier status at 6 months after enrollment and an OR of 1.745 at 12 months. Patients who improved clinically to remission while in CCM had decreased odds of outlier status for outpatient utilization at 6 and 12 months when controlling for all other study variables. Improvement in health care outcomes by CCM could translate into decreased outpatient utilization for depressed patients. ( Population Health Management 2014;17:48–53)
Stiripentol in D ravet syndrome: Results of a retrospective U . S . study
Laux, Linda , Franz, David Neal , Sullivan, Joseph , Saneto, Russell P. , Morse, Richard P., Devinsky, Orrin , Chugani, Harry T. , Hernandez, Angel , Hamiwka, Lorie, Mikati, Mohamad A. , Valencia, Ignacio , Guern, Marie–Emmanuelle Le, Chancharme, Laurent , Menezes, Márcio Sotero de, Wirrell, Elaine C., Wirrell, Elaine , Mikati, Mohamad A , Devinsky, Orrin

Epilepsia | July 12, 2013 | Volume: 54 | Issue: 9 | Pages: 1595-1604

10.1111/epi.12303 | PMID 23848835 Get It

Summary Purpose To review the efficacy and tolerability of stiripentol in the treatment of U . S . children with D ravet syndrome. Methods U . S . clinicians who had prescribed stiripentol for two or more children with D ravet syndrome between March 2005 and 2012 were contacted to request participation in this retrospective study. Data collected included overall seizure frequency, frequency of prolonged seizures, and use of rescue medications and emergency room ( ER )/hospital visits in the year preceding stiripentol initiation, and with stiripentol therapy. We separately assessed efficacy in the following treatment groups: g roup A , stiripentol without clobazam or valproate; g roup B , stiripentol with clobazam but without valproate; g roup C , stiripentol with valproate but without clobazam; and g roup D , stiripentol with clobazam and valproate. In addition, adverse effects were recorded. Key Findings Thirteen of 16 clinicians contacted for study participated and provided data on 82 children. Stiripentol was initiated a median of 6.0 years after seizure onset and 1.2 years after diagnosis of D ravet syndrome. Compared to baseline, overall seizure frequency was reduced in 2/6 in g roup A , 28/35 in g roup B , 8/14 in g roup C , and 30/48 in g roup D . All children with prolonged seizure frequency greater than quarterly during the baseline period experienced a reduction in this frequency on the various treatment arms with stiripentol. Similarly, 2/4 patients in g roup A , 25/25 in g roup B , 5/10 in g roup C , and 26/33 in g roup D experienced reduction in frequency of rescue medication use and 1/1 in g roup A , 12/12 in g roup B , 3/5 in g roup C , and 18/19 in group D had reduction in frequency of ER /hospital visits. Adverse effects were reported in 38, most commonly sedation and reduced appetite. Four patients (5%) discontinued stiripentol for adverse effects and two (2%) for lack of efficacy. Significance Stiripentol is an effective and well‐tolerated therapy that markedly reduced frequency of prolonged seizures in D ravet syndrome.
A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)a
Baron, Ellen Jo , Weinstein, Melvin P., Richter, Sandra S. , Gilligan, Peter H., Thomson, Richard B., Bourbeau, Paul, Kehl, Sue C., Robinson-Dunn, Barbara, Schwartzman, Joseph D., Chapin, Kimberle, Snyder, James W. , Forbes, Betty A., Patel, Robin , Rosenblatt, Jon E., Pritt, Bobbi S. , Miller, J. Michael , Carroll, Karen C. , Dunne, William Michael , Patel, Robin , Pritt, Bobbi S

Clinical Infectious Diseases | July 11, 2013 | Volume: 57 | Issue: 4 | Pages: e22-e121

10.1093/cid/cit278 | PMID 23845951 Get It

Abstract The critical role of the microbiology laboratory in infectious disease diagnosis calls for a close, positive working relationship between the physician and the microbiologists who provide enormous value to the health care team. This document, developed by both laboratory and clinical experts, provides information on which tests are valuable and in which contexts, and on tests that add little or no value for diagnostic decisions. Sections are divided into anatomic systems, including Bloodstream Infections and Infections of the Cardiovascular System, Central Nervous System Infections, Ocular Infections, Soft Tissue Infections of the Head and Neck, Upper Respiratory Infections, Lower Respiratory Tract infections, Infections of the Gastrointestinal Tract, Intraabdominal Infections, Bone and Joint Infections, Urinary Tract Infections, Genital Infections, and Skin and Soft Tissue Infections; or into etiologic agent groups, including Tickborne Infections, Viral Syndromes, and Blood and Tissue Parasite Infections. Each section contains introductory concepts, a summary of key points, and detailed tables that list suspected agents; the most reliable tests to order; the samples (and volumes) to collect in order of preference; specimen transport devices, procedures, times, and temperatures; and detailed notes on specific issues regarding the test methods, such as when tests are likely to require a specialized laboratory or have prolonged turnaround times. There is redundancy among the tables and sections, as many agents and assay choices overlap. The document is intended to serve as a reference to guide physicians in choosing tests that will aid them to diagnose infectious diseases in their patients.
POEMS syndrome and Castleman disease
Andhavarapu, Swati, Jiang, Liuyan

Blood | July 11, 2013 | Volume: 122 | Issue: 2 | Pages: 159-159

10.1182/blood-2013-01-477661 | PMID 24006526 Get It

Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography
Lancellotti, Patrizio , Badano, Luigi P. , Bergler‐Klein, Jutta , Bogaert, Jan , Davin, Laurent , Coucke, Philippe, Dulgheru, Raluca, Edvardsen, Thor , Gaemperli, Oliver , Griffin, Brian P. , Heidenreich, Paul A. , Plana, Juan Carlos , Port, Steven C. , Scherrer‐Crosbie, Marielle , Schwartz, Ronald G. , Sebag, Igal A., Voigt, Jens‐Uwe , Wann, Samuel , Yang, Phillip C. , Nkomo, Vuyisile T. , Cosyns, Bernard , Galderisi, Maurizio , Nieman, Koen , Voigt, Jens-Uwe

European Heart Journal – Cardiovascular Imaging | July 11, 2013 | Volume: 14 | Issue: 8 | Pages: 721-740

10.1093/ehjci/jet123 | PMID 23847385 Get It

Abstract Cardiac toxicity is one of the most concerning side effects of anti-cancer therapy. The gain in life expectancy obtained with anti-cancer therapy can be compromised by increased morbidity and mortality associated with its cardiac complications. While radiosensitivity of the heart was initially recognized only in the early 1970s, the heart is regarded in the current era as one of the most critical dose-limiting organs in radiotherapy. Several clinical studies have identified adverse clinical consequences of radiation-induced heart disease (RIHD) on the outcome of long-term cancer survivors. A comprehensive review of potential cardiac complications related to radiotherapy is warranted. An evidence-based review of several imaging approaches used to detect, evaluate, and monitor RIHD is discussed. Recommendations for the early identification and monitoring of cardiovascular complications of radiotherapy by cardiac imaging are also proposed.
Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients
Rabe, Kari G. , Call, Timothy G. , Leis, José F., Schwager, Susan M., Hanson, Curtis A. , Macon, William R. , Parikh, Sameer A. , Zent, Clive S. , Habermann, Thomas M. , Ding, Wei , Kay, Neil E. , Slager, Susan L. , Shanafelt, Tait D. , Chaffee, Kari G.

British Journal of Haematology | July 11, 2013 | Volume: 162 | Issue: 6 | Pages: 774-782

10.1111/bjh.12458 | PMID 23841899 Get It

SummaryNearly all information about patients with chronic lymphocytic leukaemia (CLL) who develop diffuse large B‐cell lymphoma [Richter syndrome (RS)] is derived from retrospective case series or patients treated on clinical trials. We used the Mayo Clinic CLL Database to identify patients with newly diagnosed CLL between January 2000 and July 2011. Individuals who developed biopsy‐proven RS during follow‐up were identified. After a median follow‐up of 4 years, 37/1641 (2·3%) CLL patients developed RS. The rate of RS was approximately 0·5%/year. Risk of RS was associated with advanced Rai stage at diagnosis (P < 0·001), high‐risk genetic abnormalitites on fluorescence in situ hybridization (P < 0·0001), unmutated IGHV (P = 0·003), and expression of ZAP70 (P = 0·02) and CD38 (P = 0·001). The rate of RS doubled in patients after treatment for CLL (1%/year). Stereotyped B‐cell receptors (odds‐ratio = 4·2; P = 0·01) but not IGHV4‐39 family usage was associated with increased risk of RS. Treatment with combination of purine analogues and alkylating agents increased the risk of RS three‐fold (odds‐ratio = 3·26, P = 0·0003). Median survival after RS diagnosis was 2·1 years. The RS prognosis score stratified patients into three risk groups with median survivals of 0·5 years, 2·1 years and not reached. Both underlying characteristics of the CLL clone and subsequent CLL therapy influence the risk of RS. Survival after RS remains poor and new therapies are needed.
Impact of radiotherapy on surgical repair and outcome in patients with rectourethral fistula
Beddy, David, Poškus, Tomas , Umbreit, Eric , Elliott, Daniel S. , Dozois, Eric J. , Larson, David W.

Colorectal Disease | July 11, 2013 | Volume: 15 | Issue: 12 | Pages: 1515-1520

10.1111/codi.12350 | PMID 23841640 Get It

AbstractAimMost patients presenting with rectourethral fistula acquire it as a complication of radiotherapy for prostate cancer, as a result of injury to the rectum during prostatectomy, through trauma or from Crohn's disease. This study examined whether choice of operation and results of surgery for rectourethral fistula are influenced by prior radiotherapy.MethodMale patients undergoing surgery for rectourethral fistula were identified from a prospectively maintained database. Data regarding aetiology, surgical treatment and outcomes were analysed.ResultsFifty patients (median age = 65.5 years) were identified. Radiation was received by 29 patients for prostate or rectal cancer, and 21 patients developed a fistula following prostatectomy, Crohn's disease or pelvic fracture (without radiation). Prior to definitive surgery, 30 patients underwent fecal diversion and 37 underwent urinary diversion. In total, 57 repairs were performed (44 patients had one repair, five patients had two and one patient had three). Definitive surgery was approached predominantly abdominally in radiated patients (90.6 vs 9.3%, P < 0.001) and perineally in nonradiated patients (80 vs 20%, P < 0.001). Successful primary fistula repair was more frequent in the nonradiated group compared with the radiated group (80.9 vs 0%, P < 0.001). Permanent colostomy and urinary diversion were more often required in radiated patients than in nonradiated patients (colostomy: 83 vs 0%, P < 0.001; urorostomy: 100 vs 19%, P < 0.001).ConclusionFew patients with radiation‐induced rectourethral fistula avoid permanent colostomy and urostomy. In contrast, most patients with nonradiation‐related fistulae undergo successful perineal repair without permanent faecal and urinary diversion.
The failing Fontan: what’s NEXT…?
Sowell, SR, Willis, BC, Je, Lane, Pierce, C.N., Fa, Arabia, Pophal, SG, Nigro, JJ, Sanders, Don B. , Park, Sung Sup , Derby, Christopher D. , Pophal, Stephen

Perfusion | July 11, 2013 | Volume: 29 | Issue: 1 | Pages: 89-93

10.1177/0267659113495913 | PMID 23842614 Get It

The Fontan procedure represents the final stage of the transition to single ventricle physiology. Conversion of very complex congenital heart anatomy, such as hypoplastic left heart syndrome, double-outlet right ventricle or double-inlet left ventricle, to a single ventricle has grown in popularity as morbidity and mortality have improved. As these patients grow, survivors are at risk for impaired ventricular dysfunction, plastic bronchitis, protein-losing enteropathy and late failure. Late failing Fontan patients represent a particularly vexing scenario for clinicians, as the only durable treatment option is cardiac transplantation. However, in the short-term, some of these patients require support beyond medical management, with mechanical circulatory support via extracorporeal life support or a ventricular assist device. We report the successful bridge of an adolescent female post-Fontan conversion with late severe cardiac failure. The patient was initially resuscitated with extracorporeal life support, transitioned to a single Berlin Heart EXCOR® ventricular assist device and, subsequently, underwent successful cardiac transplantation.
Ninety-Minute vs 3-h Performance of High-Sensitivity Cardiac Troponin Assays for Predicting Hospitalization for Acute Coronary Syndrome
Kavsak, Peter A. , Worster, Andrew , You, John J. , Oremus, Mark , Shortt, Colleen , Phan, Kim , Sohn, K.-Y. , Veljkovic, Kika, Devereaux, P.J. , Hill, Stephen, Bhanich-Supapol, Wendy, Jaffe, Allan S. , Jaffe, Allan S. , Kavsak, Peter

Clinical Chemistry | July 11, 2013 | Volume: 59 | Issue: 9 | Pages: 1407-1410

10.1373/clinchem.2013.208595 | PMID 23842201 Get It